NRIX: Nurix Therapeutics, Inc.
Performance
NRIX +31.11%
Watchlist
Select an item
Summary
NRIX at a glance
NRIX returned +31.11% over the past year and -13.81% a year over five years. Its worst drop in that year was -46.60%, smaller than 27% of stocks on Redstone, and its Sharpe ratio of 0.72 beats 61% of stocks on Redstone. It pays no dividends.
Current Drawdown
-41.92%
Rolling Volatility
142.21%
Actions
Metrics
Risk Indicators
Alpha38.64%
Beta0.99x
Sharpe0.72
Sortino0.98
Omega1.16
Calmar0.67
Martin2.67
Profile
About NRIX
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $1.8B
- Listed
- Jul 2020
- Employees
- 357
- Headquarters
- Brisbane, CA
- Website
- nurixtx.com
Comparisons